TapewireFind a company

person · Reporting owner

ALDRICH RICHARD

Disclosed activity across 3 companies

Tapewire entity
115912
SEC CIK
0001185039

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
KalVista Pharmaceuticals, Inc.KALV · Entity 39180DirectorOctober 03, 2018October 05, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

KalVista Pharmaceuticals, Inc.

Report date October 03, 2018 · Filed October 05, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.65 · Expires 2028-10-02Direct7,000 Reported balance After 2018-10-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-10-03 · Grant · Acquired 7,000 · Balance 7,000

F1: The option vests over a 12 month period: 1/12th on November 3, 2018, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests over a 12 month period: 1/12th on November 3, 2018, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CONCERT PHARMACEUTICALS, INC.

Report date March 06, 2023 · Filed March 06, 2023

Section 16 reporting ended · disclosed 2023-03-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-03-06 transaction · row 1 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 1 · 2023-03-06 · Other · Disposed 342,100 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)

F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-03-06 transaction · row 2 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 2 · 2023-03-06 · Disposition to issuer · Disposed 16,400 · Balance 0

F3: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest.

Common StockSEC Table I · non-derivativeIndirectBy Richard H. Aldrich 2018 Revocable Trust0 Reported balance After 2023-03-06 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2023-03-06 · Other · Disposed 210,526 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)

F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.

F4: Shares held by the Richard H. Aldrich 2018 Revocable Trust. Mr. Aldrich is the sole trustee of the Richard H. Aldrich 2018 Revocable Trust. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Little Eagles, LLC0 Reported balance After 2023-03-06 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2023-03-06 · Other · Disposed 44,351 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)

F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.

F5: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are the Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of the Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of the Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.42 · Expires 2025-06-10Direct0 Reported balance After 2023-03-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2026-06-08Direct0 Reported balance After 2023-03-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.29 · Expires 2027-06-14Direct0 Reported balance After 2023-03-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.59 · Expires 2028-06-13Direct0 Reported balance After 2023-03-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2023-03-06 · Disposition to issuer · Disposed 15,940 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.02 · Expires 2029-06-12Direct0 Reported balance After 2023-03-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.16 · Expires 2030-06-10Direct0 Reported balance After 2023-03-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2023-03-06 · Disposition to issuer · Disposed 23,260 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.26 · Expires 2031-06-09Direct0 Reported balance After 2023-03-06 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2023-03-06 · Disposition to issuer · Disposed 40,432 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2032-06-08Direct0 Reported balance After 2023-03-06 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2023-03-06 · Disposition to issuer · Disposed 22,410 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)

F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.

F3: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest.

F4: Shares held by the Richard H. Aldrich 2018 Revocable Trust. Mr. Aldrich is the sole trustee of the Richard H. Aldrich 2018 Revocable Trust. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

F5: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are the Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of the Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of the Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Tempest Therapeutics, Inc.

Report date December 07, 2018 · Filed December 11, 2018

Section 16 reporting ended · disclosed 2018-12-11. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect6,169 Reported balance After 2018-12-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2018-12-07 · Grant · Acquired 755 · Balance 6,169

F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

Common StockSEC Table I · non-derivativeIndirectBy Little Eagles, LLC22,000 Reported balance Holding disclosure · report date 2018-12-07 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 22,000

F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

F3: The owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Richard H. Aldrich 2005 Revocable Trust44,546 Reported balance Holding disclosure · report date 2018-12-07 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 44,546

F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

F4: The trustee of the Richard H. Aldrich 2005 Revocable Trust is the Reporting Person and he exercises sole voting and investment power over the shares of record held by the trust.

Common StockSEC Table I · non-derivativeIndirectBy Longwood Fund III LP64,137 Reported balance Holding disclosure · report date 2018-12-07 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 64,137

F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

F5: The securities in this line are held directly by Longwood Fund III LP. Longwood Fund III GP, LLC is the general partner of Longwood Fund III LP. Voting and investment power with respect to the shares held by Longwood Fund III LP are vested in Richard Aldrich and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers"), the managers of Longwood Fund III GP, LLC. Each of the Managers disclaims beneficial ownership of the shares held by Longwood Fund III LP, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in the report shall not be deemed an admission of beneficial ownership of the shares for the purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

F3: The owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

F4: The trustee of the Richard H. Aldrich 2005 Revocable Trust is the Reporting Person and he exercises sole voting and investment power over the shares of record held by the trust.

F5: The securities in this line are held directly by Longwood Fund III LP. Longwood Fund III GP, LLC is the general partner of Longwood Fund III LP. Voting and investment power with respect to the shares held by Longwood Fund III LP are vested in Richard Aldrich and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers"), the managers of Longwood Fund III GP, LLC. Each of the Managers disclaims beneficial ownership of the shares held by Longwood Fund III LP, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in the report shall not be deemed an admission of beneficial ownership of the shares for the purposes of Section 16 or for any other purpose.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 Disposition to issuerStock Option (Right to Buy) · Derivative 22,410 Not disclosed Strike: $5.00 Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · derivative · entry 12

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,410 shares

Expires 2032-06-08

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 Disposition to issuerStock Option (Right to Buy) · Derivative 40,432 Not disclosed Strike: $4.26 Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · derivative · entry 11

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,432 shares

Expires 2031-06-09

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 Disposition to issuerStock Option (Right to Buy) · Derivative 23,260 Not disclosed Strike: $9.16 Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · derivative · entry 10

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,260 shares

Expires 2030-06-10

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 Disposition to issuerStock Option (Right to Buy) · Derivative 10,000 Not disclosed Strike: $11.02 Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · derivative · entry 9

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2029-06-12

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 Disposition to issuerStock Option (Right to Buy) · Derivative 15,940 Not disclosed Strike: $19.59 Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · derivative · entry 8

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,940 shares

Expires 2028-06-13

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 Disposition to issuerStock Option (Right to Buy) · Derivative 10,000 Not disclosed Strike: $13.29 Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · derivative · entry 7

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2027-06-14

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 Disposition to issuerStock Option (Right to Buy) · Derivative 10,000 Not disclosed Strike: $12.96 Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · derivative · entry 6

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2026-06-08

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 Disposition to issuerStock Option (Right to Buy) · Derivative 10,000 Not disclosed Strike: $16.42 Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · derivative · entry 5

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2025-06-10

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 7)

F7 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 OtherCommon Stock 44,351 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · nonDerivative · entry 4

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Little Eagles, LLC

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)

F2 · price: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.

F5 · ownership.nature: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are the Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of the Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of the Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 OtherCommon Stock 210,526 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · nonDerivative · entry 3

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Richard H. Aldrich 2018 Revocable Trust

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)

F2 · price: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.

F4 · ownership.nature: Shares held by the Richard H. Aldrich 2018 Revocable Trust. Mr. Aldrich is the sole trustee of the Richard H. Aldrich 2018 Revocable Trust. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 Disposition to issuerCommon Stock 16,400 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · nonDerivative · entry 2

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · shares: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest.

F3 · price: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest.

Read SEC document
March 06, 2023 Filed Mar 6, 2023 11:33 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 OtherCommon Stock 342,100 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016159 · doc4.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)

F2 · price: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.

Read SEC document
June 09, 2022 Filed Jun 13, 2022 16:12 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantStock Option (right to buy) · Derivative 22,410 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001209191-22-036282 · doc4.xml · derivative · entry 4

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,410

Underlying: Common Stock · 22,410 shares

Expires 2032-06-08

F5 · security: This option was granted based on Mr. Aldrich's election to receive his annual cash compensation in the form of a stock option.

F6 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 9, 2023, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 9, 2023).

Read SEC document
June 09, 2022 Filed Jun 13, 2022 16:12 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantCommon Stock 16,400 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-036282 · doc4.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,500

F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 9, 2023 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant.

F2 · price: Not applicable.

Read SEC document
June 06, 2022 Filed Jun 6, 2022 17:11 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 PurchaseCommon Stock 210,526 $4.75 $999,998.50
Disclosure

SEC source: 0001209191-22-034578 · doc4.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Richard H. Aldrich 2018 Revocable Trust

Disclosed balance after: 210,526

F1 · kind: These shares were purchased as part of an underwritten public offering of common stock by the Issuer.

F2 · ownership.nature: Shares held by the Richard H. Aldrich 2018 Revocable Trust. Mr. Aldrich is the sole trustee of the Richard H. Aldrich 2018 Revocable Trust. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document
June 10, 2021 Filed Jun 11, 2021 08:36 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantStock Option (right to buy) · Derivative 30,182 $0.00 Strike: $4.26 $0.00
Disclosure

SEC source: 0001209191-21-039739 · doc4.xml · derivative · entry 4

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,182

Underlying: Common Stock · 30,182 shares

Expires 2031-06-09

F5 · security: This option was granted based on Mr. Aldrich's election to receive his annual cash compensation in the form of a stock option.

F4 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 10, 2022, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 10, 2022).

Read SEC document
June 10, 2021 Filed Jun 11, 2021 08:36 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantStock Option (right to buy) · Derivative 10,250 $0.00 Strike: $4.26 $0.00
Disclosure

SEC source: 0001209191-21-039739 · doc4.xml · derivative · entry 3

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,250

Underlying: Common Stock · 10,250 shares

Expires 2031-06-09

F4 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 10, 2022, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 10, 2022).

Read SEC document
June 10, 2021 Filed Jun 11, 2021 08:36 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantCommon Stock 5,125 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-039739 · doc4.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,100

F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 10, 2022 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant.

F2 · price: Not applicable.

Read SEC document
June 11, 2020 Filed Jun 12, 2020 16:58 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantStock Option (right to buy) · Derivative 13,260 $0.00 Strike: $9.16 $0.00
Disclosure

SEC source: 0001209191-20-036333 · doc4.xml · derivative · entry 2

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,260

Underlying: Common Stock · 13,260 shares

Expires 2030-06-10

F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 11, 2021, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 11, 2021).

F2 · derivative.exercise_date: This option was granted to the director based on such director's election to receive annual cash compensation in the form of a stock option.

Read SEC document
June 11, 2020 Filed Jun 12, 2020 16:58 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $9.16 $0.00
Disclosure

SEC source: 0001209191-20-036333 · doc4.xml · derivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-10

F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 11, 2021, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 11, 2021).

Read SEC document
June 13, 2019 Filed Jun 17, 2019 21:14 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantNonstatutory Stock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $11.02 $0.00
Disclosure

SEC source: 0001209191-19-037570 · doc4.xml · derivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-12

F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 13, 2020.

Read SEC document
December 07, 2018 Filed Dec 11, 2018 19:30 UTC Tempest Therapeutics, Inc. MLND · Entity 7734 GrantCommon Stock 755 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-062104 · doc4.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,169

F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F2 · shares: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

F1 · price: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F2 · balance_after: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

Read SEC document
November 15, 2018 Filed Nov 15, 2018 17:21 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 PurchaseCommon Stock 40,000 $11.78 $471,268.00
Disclosure

SEC source: 0001209191-18-058781 · doc4.xml · nonDerivative · entry 2

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 336,975

F2 · price: The range of prices for the transaction reported on this line was $11.625 to $12.00. The average price was $11.7817. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
November 15, 2018 Filed Nov 15, 2018 17:21 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 PurchaseCommon Stock 10,000 $12.00 $119,994.00
Disclosure

SEC source: 0001209191-18-058781 · doc4.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 296,975

F1 · price: The range of prices for the transaction reported on this line was $11.97 to $12.00. The average price was $11.9994. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
October 03, 2018 Filed Oct 5, 2018 18:03 UTC KalVista Pharmaceuticals, Inc. KALV · Entity 39180 GrantDirector Stock Option (Right to Buy) · Derivative 7,000 $0.00 Strike: $22.65 $0.00
Disclosure

SEC source: 0001567619-18-003781 · doc1.xml · derivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2028-10-02

F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 3, 2018, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 18:03 UTC Tempest Therapeutics, Inc. OVAS · Entity 7734 GrantCommon Stock 14,558 $0.00 $0.00
Disclosure

SEC source: 0001179110-18-011954 · edgar.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,220

F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F1 · price: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

Read SEC document
July 04, 2018 Filed Jul 6, 2018 18:31 UTC Tempest Therapeutics, Inc. OVAS · Entity 7734 GrantStock Option (right to buy) · Derivative 12,000 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0001179110-18-009532 · edgar.xml · derivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2028-07-04

F1 · derivative.exercise_date: The stock option will vest in twelve equal monthly installments at the end of each successive month following July 4, 2018.

Read SEC document
June 29, 2018 Filed Jul 3, 2018 16:35 UTC Tempest Therapeutics, Inc. OVAS · Entity 7734 GrantCommon Stock 11,709 $0.00 $0.00
Disclosure

SEC source: 0001179110-18-009346 · edgar.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,662

F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F1 · price: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

Read SEC document
June 14, 2018 Filed Jun 18, 2018 18:55 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantNonstatutory Stock Option (Right to Buy) · Derivative 5,940 $0.00 Strike: $19.59 $0.00
Disclosure

SEC source: 0000899243-18-017069 · doc4.xml · derivative · entry 2

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,940

Underlying: Common Stock · 5,940 shares

Expires 2028-06-13

F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019.

F2 · derivative.exercise_date: These options were awarded to the director per such director's election to receive annual cash compensation in the form of stock options.

Read SEC document
June 14, 2018 Filed Jun 18, 2018 18:55 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 GrantNonstatutory Stock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $19.59 $0.00
Disclosure

SEC source: 0000899243-18-017069 · doc4.xml · derivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2028-06-13

F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019.

Read SEC document
March 30, 2018 Filed Apr 3, 2018 17:25 UTC Tempest Therapeutics, Inc. OVAS · Entity 7734 GrantCommon Stock 13,101 $0.00 $0.00
Disclosure

SEC source: 0001179110-18-005301 · edgar.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,953

F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F1 · price: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $10,625 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

Read SEC document
February 01, 2018 Filed Feb 1, 2018 16:36 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 1,946 $19.99 $38,900.54
Disclosure

SEC source: 0001209191-18-006478 · doc4.xml · nonDerivative · entry 4

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 31, 2018 Filed Feb 1, 2018 16:36 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 300 $21.29 $6,387.00
Disclosure

SEC source: 0001209191-18-006478 · doc4.xml · nonDerivative · entry 3

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F5 · price: The range of prices for the transaction reported on this line was $21.25 to $21.33. The average weighted price was $21.29. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 31, 2018 Filed Feb 1, 2018 16:36 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 4,700 $20.78 $97,666.00
Disclosure

SEC source: 0001209191-18-006478 · doc4.xml · nonDerivative · entry 2

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,246

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F4 · price: The range of prices for the transaction reported on this line was $20.23 to $21.23. The average weighted price was $20.78. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 30, 2018 Filed Feb 1, 2018 16:36 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $21.33 $106,650.00
Disclosure

SEC source: 0001209191-18-006478 · doc4.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 6,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F2 · price: The range of prices for the transaction reported on this line was $20.80 to $21.65. The average weighted price was $21.33. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 29, 2018 Filed Jan 29, 2018 17:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $21.36 $106,800.00
Disclosure

SEC source: 0001209191-18-005919 · doc4.xml · nonDerivative · entry 4

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 11,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F7 · price: The range of prices for the transaction reported on this line was $20.75 to $21.68. The average weighted price was $21.36. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 26, 2018 Filed Jan 29, 2018 17:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $20.46 $102,300.00
Disclosure

SEC source: 0001209191-18-005919 · doc4.xml · nonDerivative · entry 3

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 16,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F6 · price: The range of prices for the transaction reported on this line was $20.34 to $20.67. The average weighted price was $20.46. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 25, 2018 Filed Jan 29, 2018 17:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 3,054 $20.22 $61,751.88
Disclosure

SEC source: 0001209191-18-005919 · doc4.xml · nonDerivative · entry 2

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 44,351

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F4 · price: The range of prices for the transaction reported on this line was $20.03 to $20.40. The average weighted price was $20.22. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5 · ownership.nature: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document
January 25, 2018 Filed Jan 29, 2018 17:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $20.31 $101,550.00
Disclosure

SEC source: 0001209191-18-005919 · doc4.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 21,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F2 · price: The range of prices for the transaction reported on this line was $20.01 to $20.74. The average weighted price was $20.31. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 24, 2018 Filed Jan 24, 2018 16:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.83 $99,150.00
Disclosure

SEC source: 0001209191-18-005145 · doc4.xml · nonDerivative · entry 6

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 47,405

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F8 · price: The range of prices for the transaction reported on this line was $19.61 to $20.00. The average weighted price was $19.83. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5 · ownership.nature: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document
January 24, 2018 Filed Jan 24, 2018 16:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.83 $99,150.00
Disclosure

SEC source: 0001209191-18-005145 · doc4.xml · nonDerivative · entry 5

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 26,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F8 · price: The range of prices for the transaction reported on this line was $19.61 to $20.00. The average weighted price was $19.83. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 23, 2018 Filed Jan 24, 2018 16:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.68 $98,400.00
Disclosure

SEC source: 0001209191-18-005145 · doc4.xml · nonDerivative · entry 4

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 52,405

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F7 · price: The range of prices for the transaction reported on this line was $19.47 to $19.85. The average weighted price was $19.68. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5 · ownership.nature: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document
January 23, 2018 Filed Jan 24, 2018 16:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.67 $98,350.00
Disclosure

SEC source: 0001209191-18-005145 · doc4.xml · nonDerivative · entry 3

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 31,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F6 · price: The range of prices for the transaction reported on this line was $19.47 to $19.85. The average weighted price was $19.67. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 22, 2018 Filed Jan 24, 2018 16:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.54 $97,700.00
Disclosure

SEC source: 0001209191-18-005145 · doc4.xml · nonDerivative · entry 2

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 57,405

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F4 · price: The range of prices for the transaction reported on this line was $19.37 to $19.84. The average weighted price was $19.54. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5 · ownership.nature: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document
January 22, 2018 Filed Jan 24, 2018 16:43 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.55 $97,750.00
Disclosure

SEC source: 0001209191-18-005145 · doc4.xml · nonDerivative · entry 1

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 36,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F2 · price: The range of prices for the transaction reported on this line was $19.41 to $19.82. The average weighted price was $19.55. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 19, 2018 Filed Jan 19, 2018 16:34 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.65 $98,250.00
Disclosure

SEC source: 0001209191-18-004565 · doc4.xml · nonDerivative · entry 6

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 62,405

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F9 · price: The range of prices for the transaction reported on this line was $19.39 to $19.82. The average weighted price was $19.65. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5 · ownership.nature: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document
January 19, 2018 Filed Jan 19, 2018 16:34 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.66 $98,300.00
Disclosure

SEC source: 0001209191-18-004565 · doc4.xml · nonDerivative · entry 5

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 41,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F8 · price: The range of prices for the transaction reported on this line was $19.49 to $19.82. The average weighted price was $19.66. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 18, 2018 Filed Jan 19, 2018 16:34 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.43 $97,150.00
Disclosure

SEC source: 0001209191-18-004565 · doc4.xml · nonDerivative · entry 4

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 67,405

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F7 · price: The range of prices for the transaction reported on this line was $19.16 to $19.76. The average weighted price was $19.43. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5 · ownership.nature: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document
January 18, 2018 Filed Jan 19, 2018 16:34 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.36 $96,800.00
Disclosure

SEC source: 0001209191-18-004565 · doc4.xml · nonDerivative · entry 3

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 46,946

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F6 · price: The range of prices for the transaction reported on this line was $19.14 to $19.77. The average weighted price was $19.36. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Shares held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc. Mr. Aldrich is the sole stockholder of Little Bear Associates, Inc.

Read SEC document
January 17, 2018 Filed Jan 19, 2018 16:34 UTC CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 SaleCommon Stock 5,000 $19.03 $95,150.00
Disclosure

SEC source: 0001209191-18-004565 · doc4.xml · nonDerivative · entry 2

ALDRICH RICHARD · CIK 0001185039 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 72,405

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 13, 2017.

F4 · price: The range of prices for the transaction reported on this line was $19.00 to $19.14. The average weighted price was $19.03. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5 · ownership.nature: Shares held by Little Eagles, LLC. The owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.